Allergan Biocell Textured Breast Implant Products Liability Litigation
The causation theory is supported by scientific evidence indicating that textured surfaces, especially macrotextured implants like Allergan BIOCELL, promote chronic inflammation. This persistent inflammatory response is believed to lead to T-cell proliferation and the development of BIA-ALCL. The FDA's 2019 recall of Allergan BIOCELL implants was based on data showing a higher-than-expected incidence of BIA-ALCL in women with these implants. Long-term studies suggest that the risk increases after approximately 10 years of implantation, with the pathogenesis involving immune response to the textured surface, genetic susceptibility, and chronic inflammation.
1,496
Pending actions
1,578
Total actions filed
Active
Status
12/18/2019
Established
Who qualifies
Plaintiffs qualify if they have received Allergan BIOCELL textured breast implants and have been diagnosed with BIA-ALCL or systemic autoimmune disorders after implantation. Diagnoses should occur within a timeframe that is consistent with the long latency period of BIA-ALCL, typically around 10 years post-implantation, but specific timeframes may vary. Plaintiffs may include women who have undergone prophylactic mastectomies or are breast cancer survivors, with claims focusing on the design, manufacture, and safety of the implants.
Products involved
- Allergan BIOCELL textured breast implants
Alleged injuries
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- systemic autoimmune or connective tissue disorders such as Sjögren's syndrome, rheumatoid arthritis, systemic sclerosis
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
